In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 0.91 below Mink Therapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 115 other companies have achieved higher Quick Ratio than Mink Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 1328 to 2054.

Explain Quick Ratio?
How much Cash & cash equivalents INKT�s has?
What are INKT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/INKT/financial-strength

https://api.csimarket.com/api/v1/companies/INKT/fundamentals

https://api.csimarket.com/api/v1/companies/INKT/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

INKT Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	6.06 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-21.36 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.91	Subscribe	Subscribe	Subscribe	Subscribe
INKT's Total Ranking	# 2054	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	8.01 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-15.17 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 116
Healthcare Sector	# 650
Overall Market	# 2054

Quick Ratio Statistics
High	Average	Low
2.67	1.1	0.01
(Dec 31 2025)		(Sep 30 2021)

Financial Statements
Mink Therapeutics Inc 's Current Liabilities	$ 8 Millions	Visit INKT's Balance sheet
Mink Therapeutics Inc 's Cash & cash equivalent	$ 7 Millions	Visit INKT's Balance sheet
Source of INKT's Sales		Visit INKT's Sales by Geography

Cumulative Mink Therapeutics Inc 's Quick Ratio

INKT's Quick Ratio for the trailling 12 Months

INKT Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-13.17 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	106.19 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.54	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 1956	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	1.87 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-4.93 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to INKT Financial Strength Comparisons >> Go to Compare INKT Quick Ratio to its Competitors

News about Mink Therapeutics Inc Quick Ratio

MiNK Therapeutics Raises $5.8 Million in Private Placement and Bolsters Clinical Trials with Board Observer Appointment

MiNK Therapeutics Secures $5.8 Million in Private Placement and Adds Board Observer for Accelerated Clinical Trials of MiNK-215
NEW YORK, May 13, 2024 - MiNK Therapeutics, Inc. (NASDAQ: INKT), a trailblazing clinical-stage biopharmaceutical company focused on the development, discovery, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies, has recently announced a significant milestone in its journey. The company disclosed that it has entered into a stock purchase agreement, raising $5.8 million through a private placement financing (PIPE). The newly infused capital will be directed towards expediting the clinical trials of MiNK-215, their leading allogeneic CAR-iNKT cell therapy aimed at targeting fibroblast activation protein (FAP) in solid tumors. MiNK Therapeutics plans to initiate clinical testing for MiNK-215 in early 2025.
The successful completion of this private placement financing signifies a new chapter of progress for MiNK Therapeutics. By securing $5.8 million in additional funds, the company is empowered to accelerate the advancement of MiNK-215, a promising iNKT cell therapy that has demonstrated remarkable potential in combating solid tumors. With solid tumors accounting for a significant portion of cancer cases worldwide, the urgent need for effective treatment options has been a driving force behind MiNK Therapeutics ongoing research and development efforts.

On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2026 to $8.18 millions, cumulative Quick Ratio decreased to 1.54 above the INKT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 145 other companies have achieved higher Quick Ratio than Mink Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 3511, from total ranking during the twelve months ending second quarter 2026 at 4019.

Explain Quick Ratio?
How much Cash & cash equivalents INKT�s has?
What are INKT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 146
Healthcare Sector	# 916
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
1.79	0.87	0.4
(Sep 30 2022)		(Jun 30 2025)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Vericel Corporation	2.44	$ 133.493 Millions	$ 54.719 Millions
Adma Biologics Inc	2.25	$ 124.555 Millions	$ 55.475 Millions
Cullinan Therapeutics Inc	2.20	$ 88.260 Millions	$ 40.130 Millions
Exelixis Inc	2.17	$ 892.018 Millions	$ 411.877 Millions
Halozyme Therapeutics Inc	2.12	$ 1,074.480 Millions	$ 506.173 Millions
Relay Therapeutics Inc	2.10	$ 124.184 Millions	$ 59.154 Millions
Biocryst Pharmaceuticals Inc	1.92	$ 375.334 Millions	$ 195.830 Millions
Novavax inc	1.89	$ 622.363 Millions	$ 329.845 Millions
Elutia Inc	1.81	$ 29.093 Millions	$ 16.030 Millions
Lenz Therapeutics Inc	1.78	$ 31.610 Millions	$ 17.750 Millions
Acumen Pharmaceuticals Inc	1.74	$ 78.604 Millions	$ 45.087 Millions
Prime Medicine Inc	1.72	$ 61.157 Millions	$ 35.635 Millions
Sana Biotechnology Inc	1.63	$ 121.728 Millions	$ 74.880 Millions
Kodiak Sciences Inc	1.62	$ 88.678 Millions	$ 54.739 Millions
Aligos Therapeutics Inc	1.59	$ 31.094 Millions	$ 19.600 Millions
Atara Biotherapeutics Inc	1.51	$ 9.917 Millions	$ 6.568 Millions
Tarsus Pharmaceuticals Inc	1.36	$ 309.612 Millions	$ 227.114 Millions
Metagenomi Therapeutics Inc	1.12	$ 36.107 Millions	$ 32.340 Millions
Amgen Inc	1.11	$ 25,811.000 Millions	$ 23,231.000 Millions
Coherus Oncology inc	1.11	$ 83.629 Millions	$ 75.636 Millions
Biocardia Inc	1.06	$ 2.224 Millions	$ 2.092 Millions
Sab Biotherapeutics Inc	0.98	$ 14.438 Millions	$ 14.798 Millions
Passage Bio Inc	0.97	$ 20.160 Millions	$ 20.743 Millions
Bio techne Corp	0.97	$ 350.036 Millions	$ 361.269 Millions
Mink Therapeutics Inc	0.91	$ 7.471 Millions	$ 8.175 Millions
C4 Therapeutics Inc	0.81	$ 33.492 Millions	$ 41.460 Millions
Allogene Therapeutics Inc	0.76	$ 29.270 Millions	$ 38.498 Millions
Protalix Biotherapeutics inc	0.73	$ 22.035 Millions	$ 30.233 Millions
Ocugen Inc	0.71	$ 84.257 Millions	$ 118.901 Millions
Neurocrine Biosciences Inc	0.59	$ 739.100 Millions	$ 1,242.800 Millions

Date modified: 2026-11-13T08:43:01+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.